An interventional study of VATS hyperthermic chemoperfusion and Bedside talc slurry pleurodesis in Safety of Intervention, Efficacy of Intervention and Cost Effectiveness, sponsored by Theagenio Cancer Hospital. Completed at 1 site in Greece. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2014-11-17.
Sponsored by Theagenio Cancer Hospital · Not applicable, Interventional, and Treatment
Aim of this study is to compare two methods of pleurodesis for refractory malignant pleural effusions, in terms of safety and efficacy.
The study compares prospectively two groups of patients with refractory maignant pleural effusion. Group A consists of patients undergoing video-assisted hyperthermic pleural chemoperfusion (with a pump machine) and group B includes patients undergoing bed-side tube thoracostomy and talc slurry pleurodesis.
335 studies on the registry are indexed under Pleural Effusion; 63 are open to participants now.
This study's enrollment of 60 is close to the median of 62 across 220 interventional studies indexed under Pleural Effusion.
Browse Pleural Effusion studies →Theagenio Cancer Hospital is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patients undergo a VATS drainage of pleural effusion with adhesiolysis and complete mobilization of the lung, following by a 1 hour hyperthermic (40oC)chemoperfusion by means of a pump machine.
Procedure: VATS hyperthermic chemoperfusion
The patients undergo tube thoracostomy under local anesthesia. When the lung is fully expanded, talc slurry bed-side pleurodesis is performed.
Procedure: Bedside talc slurry pleurodesis
VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
Recurrence of pleural effusion
Time frame: 2 months following intervention
Morbidity
Time frame: Postoperative period (7 days following intervention)
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Theagenio Cancer Hospital